Eptifibatide-induced thrombocytopenia and coronary bypass operation
نویسندگان
چکیده
منابع مشابه
Some reflections on the coronary bypass operation.
SUMMARY A promising new operation-coronary bypass-has been developed for the treatment of coronary heart disease. However, because of the nature of the underlying disease and the minute size of the vessels to be anastomosed, its long-range prospects are in doubt. At this point in time there is no evidence that the operation either prevents infarction or prolongs life, and great caution is urged...
متن کاملProfound thrombocytopenia after primary exposure to eptifibatide
Eptifibatide is a glycoprotein IIb/IIIa receptor antagonist used to reduce the incidence of ischemic events in patients with acute coronary syndromes and those undergoing percutaneous coronary intervention. A minority of patients given eptifibatide develop acute, profound thrombocytopenia (<20,000 cells/mm(3)) within a few hours of receiving the drug. This case report discusses a patient who de...
متن کاملacute severe thrombocytopenia occurring after administration of eptifibatide postpones emergent coronary artery surgery
conclusions the authors describe the second reported case of eptifibatide-induced severe thrombocytopenia associated with cardiac surgery. in this case, discontinuation of eptifibatide and transfusion of apheresis platelets increased the platelet count (137 k/ul) the following day, and the patient subsequently underwent successful coronary artery surgery using cardiopulmonary bypass. introducti...
متن کاملHeparin-induced thrombocytopenia following coronary artery bypass grafting: a diagnostic dilemma
The diagnosis of heparin-induced thrombocytopenia (HIT) is a challenge in post-cardiac surgery patients because of the high incidence of non-immune thrombocytopenia and heparin-platelet factor 4 antibodies in these groups. We present a case of HIT in a post coronary artery bypass surgery patient, which was successfully treated with prompt recognition and discontinuation of heparin products.
متن کاملAcute Severe Thrombocytopenia Occurring After Administration of Eptifibatide Postpones Emergent Coronary Artery Surgery
INTRODUCTION Eptifibatide is a platelet glycoprotein IIb/IIIa (GP IIb/IIIa) receptor antagonist that inhibits fibrinogen binding to the activated GP IIb/IIIa site and prevents platelet-platelet interaction and clot formation. GP IIb/IIIa inhibitors improve outcome in patients undergoing percutaneous coronary intervention for acute coronary syndrome. Thrombocytopenia is a complication of GP IIb/...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thrombosis and Haemostasis
سال: 2003
ISSN: 1538-7933,1538-7836
DOI: 10.1046/j.1538-7836.2003.00056.x